Njbio India Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 16.37 Cr
as on 06-07-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 8.16 Cr
as on 06-07-2024
- Revenue 114.92%
(FY 2023)
- Profit 235.45%
(FY 2023)
- Ebitda 368.98%
(FY 2023)
- Net Worth 258.45%
(FY 2023)
- Total Assets 8.21%
(FY 2023)
About Njbio India Pharmaceutical
The Corporate was formerly known as Amar Chemistry Private Limited. The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 16.37 Cr.
The company has closed loans amounting to ₹8.16 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Njbio India Pharmaceutical Private Limited India are Hetvi Sheth as COMPANY SECRETARY and Arpit Pokharna as Cfo. Arpit Pokharna and Nareshkumar Jain serve as directors at the Company.
- CIN/LLPIN
U73100MH2019PTC319319
- Company No.
319319
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jan 2019
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Njbio India Pharmaceutical?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hetvi Sheth | Company Secretary | 17-Mar-2023 | Current |
Arpit Pokharna  | CFO | 02-Jan-2023 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nareshkumar Jain  | Director | 10-Jan-2019 | Current |
Financial Performance and Corporate Structure Insights of Njbio India Pharmaceutical.
Njbio India Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 114.92% increase. The company also saw a substantial improvement in profitability, with a 235.45% increase in profit. The company's net worth Soared by an impressive increase of 258.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Njbio India Pharmaceutical?
In 2023, Njbio India Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 20 Aug 2019 | ₹8.16 Cr | Satisfied |
How Many Employees Work at Njbio India Pharmaceutical?
Njbio India Pharmaceutical has a workforce of 38 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Njbio India Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Njbio India Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
